Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

OBJECTIVES:

- Optimize and standardize the in vitro cell kill assay using human white blood cells and
human cancer cell lines from patients with metastatic cancer and from healthy
participants.

- Determine the results of the in vitro cell kill assay in patients with metastatic
cancer and in healthy participants with no history of cancer.

OUTLINE: This is a pilot study.

Peripheral blood is obtained from healthy participants and from cancer patients. Tissue is
collected from archived samples. White blood cells are obtained from tissue and blood
samples and are assessed by the in vitro cell kill assay.

PROJECTED ACCRUAL: A total of 24 patients and 24 healthy participants will be accrued for
this study.

Inclusion Criteria:

-Meets 1 of the following criteria:

- Diagnosis of metastatic cancer including, but not limited to, any of the following:

- Stage IV non-small cell lung cancer

- Extensive-stage small cell lung cancer

- Metastatic testicular cancer

- Stage IV breast carcinoma

- Stage III or IV ovarian carcinoma

- Stage IV endometrial carcinoma

- Stage IV prostate carcinoma

- Stage IV colorectal or pancreatic cancer

- Stage IV renal cancer

- Stage III or IV non-Hodgkin's lymphoma

- Stage IV bladder cancer

- Stage III multiple myeloma (Salmon-Durie staging)

- Metastatic melanoma

- Metastatic sarcoma

- Healthy participant, meeting the following criteria:

- No prior cancer

- Over 50 years of age

Exclusion Criteria:

- Serious medical or psychiatric condition that would preclude study compliance

- Chemotherapy or radiotherapy within the past 3 months (patient)

- Prior immunosuppressive therapy or radiotherapy for any disease (healthy participant)